voprecotestВопросы экономикиVoprosy Ekonomiki0042-8736Voprosy Ekonomiki, NP10.32609/0042-8736-2019-8-127-138voprecotest-2363Research ArticleНАУЧНЫЕ СООБЩЕНИЯRESEARCH NOTESРоссийские фармацевтические компании: бизнес-модели лидеров рынкаRussian pharmaceutical companies: Business models of market leadershttps://orcid.org/0000-0002-6613-7582КравченкоН. А.KravchenkoNataliya A.

Кравченко Наталия Александровна - доктор экономических наук, профессор, заведующая отделом ИЭОПП СО РАН, профессор ННИГУ.

Новосибирск

Novosibirsk

natakravchenko20@mail.ruhttps://orcid.org/0000-0003-3423-1264ЮсуповаА. Т.YusupovaAlmira T.

Юсупова Альмира Талгатовна - доктор экономических наук, профессор, ведущий научный сотрудник ИЭОПП СО РАН, профессор ННИГУ.

Новосибирск

Novosibirsk

yusupova@ieie.nsc.ruИнститут экономики и организации промышленного производства, СО РАН; Новосибирский национального исследовательский государственный университетРоссияInstitute of Economics and Industrial Engineering, Siberian Branch of the Russian Academy of Sciences; Novosibirsk State UniversityRussian Federation20190408201908127138Copyright © Voprosy Ekonomiki, NP, 20192019Voprosy Ekonomiki, NPVoprosy Ekonomiki, NPhttps://www.vopreco.ru/jour/about/submissions#copyrightNoticehttps://www.vopreco.ru/jour/article/view/2363

В работе на примере лидирующих фармацевтических компаний-произво-дителей исследуются бизнес-модели как факторы их конкурентоспособности. Представлен обзор бизнес-моделей глобальных фармацевтических компаний. На основе эмпирических данных (база СПАРК) идентифицированы российские компании-лидеры, выявлено, что они используют модели прорывных исследований, модели, направленные на рост стоимости бизнеса, и модели активного управления портфелем. Выделены особенности и перспективы развития каждого типа моделей.

Many factors influence firms’ growth possibilities and market positions. This paper deals with business models as company’s competitiveness determinant; the case of Russian leading pharmaceutical companies is studied. The review of global pharmaceutical leaders’ business models is presented. Russian leaders are indentified basing on empirical data provided by SPARK database. It has been found that they use models of disruptive research, models aimed at business value growth as well as models of active portfolio management. Characteristics and perspectives of each model type are determined.

фармацевтическая промышленностьроссийские компании-лидерыбизнес-модельpharmaceutical industryRussian leading companiesbusiness modelsИсследование выполнено по плану НИР ИЭОПП СО РАН по проекту XI.172.1.3. «Теория и методология стратегического управления развитием высокотехнологичного бизнеса как базиса новой индустриализации» № АААА-А17-117022250130-8ReferencesДелойт (2017). Тенденции фармацевтического рынка России — 2017. Система прослеживаемости лекарственных препаратов: дополнительные затраты или возможности? М.: Исследовательский центр компании «Делойт» в СНГ. https://www2.deloitte.com/content/dam/Deloitte/ru/Documents/life-sciences-health-care/russian/russian-pharmaceutical-market-trends-2017-ru.pdfDeloitte (2017). Russian pharmaceutical market trends in 2017. Track & trace system: Additional costs or opportunities? Moscow: Deloitte CIS Research Centre. https://www2.deloitte.com/content/dam/Deloitte/ru/Documents/life-sciences-health-care/russian-pharmaceutical-market-trends-2017-eng.pdfМокроусова И., Еременко Е. (2017). Короли госзаказа — 2017: Рейтинг Forbes // Forbes, 2 марта.Mokrousova I., Eremenko E. (2017). Kings of state procurement: Forbes rating. Forbes, March 2. (In Russian).Мокроусова И., Еременко Е. (2018). Короли госзаказа — 2018: Рейтинг Forbes // Forbes, 22 февраля.Mokrousova I., Eremenko E (2018). Kings of state procurement: Forbes rating. Forbes, February 22. (In Russian).Московская биржа (2017). Обзор тенденций на глобальном и российском фармацевтическом рынке. https://fs.moex.com/files/14283Moscow Exchange (2017). Overview of the global and Russian pharmaceutical market trends. (In Russian). https://fs.moex.com/files/14283Остервальдер А., Пинье И. (2018). Построение бизнес-моделей. Настольная книга стратега и новатора. М.: Альпина Паблишер.Osterwalder A., Pigneur Y. (2018). Building business models. Handbook of the strategist and innovator. Moscow: Alpina Publisher. (In Russian).Deloitte (2018). Digital strategy: Building digital bridges to end consumers. Russian pharmaceutical market trends in 2018. Moscow: Deloitte CIS Research Centre. https://www2.deloitte.com/content/dam/Deloitte/ru/Documents/life-sciences-health-care/russian-pharmaceutical-market-trends-2018-en.pdfDeloitte (2018). Digital strategy: Building digital bridges to end consumers. Russian pharmaceutical market trends in 2018. Moscow: Deloitte CIS Research Centre. https://www2.deloitte.com/content/dam/Deloitte/ru/Documents/life-sciences-health-care/russian-pharmaceutical-market-trends-2018-en.pdfDSM Group (2017). Фармацевтический рынок России 2017. Годовой отчет. http://dsm.ru/docs/analytics/Annual_Report_2017_rus.pdfDSM Group (2017). Russian pharmaceutical market 2017. Annual report. (In Russian). http://dsm.ru/docs/analytics/Annual_Report_2017_rus.pdfDSM Group (2018). Фармацевтический рынок России 2018. Годовой отчет. https://dsm.ru/docs/analytics/Annual_report_2018_DSM.pdfDSM Group (2018). Фармацевтический рынок России 2018. Годовой отчет. [DSM Group (2018). Russian pharmaceutical market 2018. Annual report. (In Russian).] https://dsm.ru/docs/analytics/Annual_report_2018_DSM.pdfCapo Fr., Brunetta F., Boccardelli P. (2014). Innovative business models in the pharmaceutical industry: A case on exploiting value networks to stay competitive. International Journal of Engineering Business Management. https://doi.org/10.5772/59155Capo Fr., Brunetta F., Boccardelli P. (2014). Innovative business models in the pharmaceutical industry: A case on exploiting value networks to stay competitive. International Journal of Engineering Business Management. https://doi.org/10.5772/59155Chesbrough H., Rosenbloom R. S. (2002). The role of the business model in capturing value from innovation: Evidence from Xerox corporation’s spin-off companies. Industrial and Corporate Change, Vol. 11, No. 3, pp. 529—555.Chesbrough H., Rosenbloom R. S. (2002). The role of the business model in capturing value from innovation: Evidence from Xerox corporation’s spin-off companies. Industrial and Corporate Change, Vol. 11, No. 3, pp. 529—555.Ehrhardt M. (2015). Is pharma ready for the future? The way medicine is manufactured is about to be radically transformed. Strategy+Business, November 30. https://www.strategy-business.com/article/00363Ehrhardt M. (2015). Is pharma ready for the future? The way medicine is manufactured is about to be radically transformed. Strategy+Business, November 30. https://www.strategy-business.com/article/00363Edmunds R., Pisani J., Strang D. (2016). Pharma’s identity crisis. Four strategies for creating value in life sciences. Strategy+Business, June 15. https://www.strategy-business.com/article/Pharmas-Identity-Crisis?gko=ac347Edmunds R., Pisani J., Strang D. (2016). Pharma’s identity crisis. Four strategies for creating value in life sciences. Strategy+Business, June 15. https://www.strategy-business.com/article/Pharmas-Identity-Crisis?gko=ac347IMAP (2016). Global M&A report. Pharma/biotech 2016. https://www.pharmablender.com/files/report/Global%20Pharma%20Biotech%20MA%20Report%202016.pdfIMAP (2016). Global M&A report. Pharma/biotech 2016. https://www.pharmablender.com/files/report/Global%20Pharma%20Biotech%20MA%20Report%202016.pdfITA (2016). 2016 top markets report pharmaceuticals. Washington, DC: International Trade Administration. https://www.trade.gov/topmarkets/pdf/Pharmaceuti-cals_Top_Markets_Reports.pdfITA (2016). 2016 top markets report pharmaceuticals. Washington, DC: International Trade Administration. https://www.trade.gov/topmarkets/pdf/Pharmaceuti-cals_Top_Markets_Reports.pdfJSB Intelligence (2005). Strategic analysis of the pharma market, future revenue models and key players. http://www.fgcasal.org/politicafarmaceutica/docs/JSB_Intelligence.PDFJSB Intelligence (2005). Strategic analysis of the pharma market, future revenue models and key players. http://www.fgcasal.org/politicafarmaceutica/docs/JSB_Intelligence.PDFKPMG (2017). Pharma outlook 2030: From evolution to revolution. KPMG Global Strategy Group. https://assets.kpmg.com/content/dam/kpmg/xx/pdf/2017/02/pharma-outlook-2030-from-evolution-to-revolution.pdfKPMG (2017). Pharma outlook 2030: From evolution to revolution. KPMG Global Strategy Group. https://assets.kpmg.com/content/dam/kpmg/xx/pdf/2017/02/pharma-outlook-2030-from-evolution-to-revolution.pdfMagretta J. (2002). Why business models matter? Harvard Business Review, Vol. 80, р. 86-92.Magretta J. (2002). Why business models matter? Harvard Business Review, Vol. 80, р. 86-92.Malone T. W., Weill P., Lai R. K., D’Urso V. T., Herman G., Apel Th. G., Woerner S. L. (2006). Do some business models perform better than others? Sloan School of Management, MIT Center for Coordination Science. MIT Sloan Research Paper, No. 4615-06.Malone T. W., Weill P., Lai R. K., D’Urso V. T., Herman G., Apel Th. G., Woerner S. L. (2006). Do some business models perform better than others? Sloan School of Management, MIT Center for Coordination Science. MIT Sloan Research Paper, No. 4615-06.Nielsen C., Lund M. (2014). An introduction to business models. In: C. Nielsen, M. Lund (eds.). The basics of business models. Copenhagen: BookBoon.com/Ventus Publishing Aps, pp. 8-20.Nielsen C., Lund M. (2014). An introduction to business models. In: C. Nielsen, M. Lund (eds.). The basics of business models. Copenhagen: BookBoon.com/Ventus Publishing Aps, pp. 8-20.Osterwalder A., Pigneur Y., Tucci L. C. (2004). Clarifying business models: Origins, present, and future of the concept. Communications of AIS, Vol. 16, pp. 1-25.Osterwalder A., Pigneur Y., Tucci L. C. (2004). Clarifying business models: Origins, present, and future of the concept. Communications of AIS, Vol. 16, pp. 1-25.Peruffo E., Pirolo L., Nenni M. E. (2014). Spin-off and innovation in the pharmaceutical industry. International Journal of Engineering Business Management. https://doi.org/10.5772/59019.Peruffo E., Pirolo L., Nenni M. E. (2014). Spin-off and innovation in the pharmaceutical industry. International Journal of Engineering Business Management. https://doi.org/10.5772/59019.PhRMA (2015). 2015 biopharmaceutical research industry profile. Washington, DC: Pharmaceutical Research and Manufacturers of America. http://phrma-docs.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdfPhRMA (2015). 2015 biopharmaceutical research industry profile. Washington, DC: Pharmaceutical Research and Manufacturers of America. http://phrma-docs.phrma.org/sites/default/files/pdf/2015_phrma_profile.pdfPricewaterhouseCoopers (2007). Pharma 2020: The vision. Which path will you take? https://www.pwc.com/gx/en/pharma-life-sciences/pdf/pharma2020final.pdfPricewaterhouseCoopers (2007). Pharma 2020: The vision. Which path will you take? https://www.pwc.com/gx/en/pharma-life-sciences/pdf/pharma2020final.pdfWeill P., Malone T. W., D’Urso V. T., Herman G., Woerner S. L. (2004). Do some business models perform better than others? A study of the 1000 largest US firms. MIT Center for Coordination Science Working Paper, No. 226.Weill P., Malone T. W., D’Urso V. T., Herman G., Woerner S. L. (2004). Do some business models perform better than others? A study of the 1000 largest US firms. MIT Center for Coordination Science Working Paper, No. 226.Weill P., Malone T. W., D’Urso V. T., Herman G., Woerner S. L. (2004). Do some business models perform better than others? A study of the 1000 largest US firms. MIT Center for Coordination Science Working Paper, No. 226.

The authors declare that there are no conflicts of interest present.